Abstract
Glioma is a relatively low aggressive brain tumor. Although the median survival time of patients for lower-grade glioma (LGG) was longer than that of patients for glioblastoma, the overall survival was still short. Therefore, it is urgent to find out more effective molecular prognostic markers. The role of the Fam20 kinase family in different tumors was an emerging research field. However, the biological function of Fam20C and its prognostic value in brain tumors have rarely been reported. This study aimed to evaluate the value of Fam20C as a potential prognostic marker for LGG. A total of 761 LGG samples (our cohort, TCGA and CGGA) were included to investigate the expression and role of Fam20C in LGG. We found that Fam20C was drastically overexpressed in LGG and was positively associated with its clinical progression. Kaplan-Meier analysis and a Cox regression model were employed to evaluate its prognostic value, and Fam20C was found as an independent risk factor in LGG patients. Gene set enrichment analysis also revealed the potential signaling pathways associated with Fam20C gene expression in LGG; these pathways were mainly enriched in extracellular matrix receptor interactions, cell adhesion, cell apoptosis, NOTCH signaling, cell cycle, etc. In summary, our findings provide insights for understanding the potential role of Fam20C and its application as a new prognostic biomarker for LGG.
Highlights
Malignant central nervous system tumors account for 31.5% of nervous system tumors, and gliomas account for 80.7% of malignant central nervous system tumors (Goodenberger and Jenkins 2012; Ostrom et al, 2018)
Data from the Cancer Cell Line Encyclopedia (CCLE) database showed that Fam20C was highly expressed in multiple cancer cell lines, especially glioma (Figure 1A)
We analyzed the correlation between the level of Fam20C mRNA in lower-grade glioma (LGG) patients and their clinicopathological parameters
Summary
Malignant central nervous system tumors account for 31.5% of nervous system tumors, and gliomas account for 80.7% of malignant central nervous system tumors (Goodenberger and Jenkins 2012; Ostrom et al, 2018). Global cancer statistics in 2018 showed that nervous system cancer was the 19th most common cancer in the world, with 296,851 new cases, accounting for 1.6% of the total cancer incidence, and 241,037 deaths each year, accounting for 2.5% of the total case mortality (Bray et al, 2018). Fam20C in Lower-Grade Glioma system classification, diffuse gliomas include WHO grade II and grade III astrocytic tumors, grade II and III oligodendrogliomas, and grade IV glioblastomas (Louis et al, 2016; Wesseling and Capper 2018). There is extensive heterogeneity among lower-grade glioma patients. It is very important to find more effective molecular prognostic markers for the treatment of patients with LGG. Understanding the pathogenesis and etiology of LGG may assist in discovering advanced treatment methods and effective biomarkers for diagnosis and prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
